Revenue recognition from Collaboration and License Agreements (Tables)

6 Months Ended

Jun. 30, 2024

Disaggregation of Revenue [Line Items]

Schedule of Revenue From Collaboration Agreements

The following table presents revenue from collaboration agreements:

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
	(in thousands)
Roche Collaboration and License Agreement	$	1,073	$	4,825	$	50,888	$	10,137
Bristol-Myers Squibb Collaboration and License Agreement		—		14,951		2,589		15,317
Ono Collaboration Agreement		—		10,473		—		10,473
Total revenue	$	1,073	$	30,249	$	53,477	$	35,927

Roche

Disaggregation of Revenue [Line Items]

Schedule of Deferred Revenue

Deferred revenue pertaining to the Roche Agreement	Completion of Continuing Trials
	(in thousands)
Balance as of December 31, 2023	$	9,463
Increase in collaboration revenue		41,425
Recognition as revenue, as the result of performance obligations satisfied		(50,888	)
Balance as of June 30, 2024	$	-

Bristol-Myers Squibb Company

Disaggregation of Revenue [Line Items]

Schedule of Deferred Revenue

Deferred revenue pertaining to the BMS Agreement	Options to license undruggable targets
	(in thousands)
Balance as of December 31, 2023	$	2,489
Increase in collaboration revenue		100
Recognition as revenue, as the result of performance obligations satisfied		(2,589	)
Balance as of June 30, 2024	$	—